AptarGroup, Inc
In the published model solve dated 2026-Q2, anchored at $132.99, AptarGroup, Inc (ATR) is priced for +8.9% growth. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. The narrative was composed July 25, 2026 from SEC EDGAR filings.
• Nearly half of revenue comes from Pharma, where the product sold is not packaging but the dispensing device written into a customer's drug submission, and the 10-K describes working ⟦"for years modifying our dispensing device to work in connection with a customer's drug formulation"⟧ before any royalty arrives. • Most of the company's production sits outside the United States, so import restrictions and a moving euro reach reported results before volumes do, and the second-quarter outlook is p
Is ATR overvalued? See what's priced in →
525 institutional managers reported holding ATR in 13F filings for the quarter ended 2026-03-31. Together they hold about 93% of the company; the top 10 hold 50%. 78 opened new positions that quarter. Held by Vanguard Group, BlackRock, Morgan Stanley, among others. On the short side, 2.3M shares were sold short as of the 2026-06-15 count, about 4% of shares outstanding (5 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
ATR has cut its share count 2.7% over the past five years, spending $751.44M on repurchases. It pays a dividend, and has paid one every year in our records (17 and counting), raised 16 years straight; the current rate is $1.83 a share annually. Cash returned over the past three years: $319.66M in dividends and $552.13M in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
No open-market insider buys on file at ATR over the trailing three years. Absence is a fact about the company, not a signal. 20 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
ATR's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-07-29 | +3.2% | +1.0% |
| 2023-10-27 | +0.1% | +2.0% |
| 2024-02-10 | +5.4% | -1.3% |
| 2024-04-27 | +2.4% | -1.8% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
ATR's latest 8-K filings: 2026-07-30 (items 2.02, 9.01); 2026-05-13 (items 5.02); 2026-05-07 (items 5.07); 2026-04-30 (items 2.02, 9.01); 2026-03-17 (items 5.02, 9.01).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: July 25, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.